Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21291787 | 1.00 | ALDH1A1 (0.58) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL9537676 | 1.00 | ALDH1A1 (0.58) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL6704420 | 1.00 | ALDH1A1 (0.58) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL64790 | 1.00 | — | — | |
| SCHEMBL30523266 | 0.97 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| Hydrochloric Acid SCHEMBL1477069 | 0.97 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL28304091 | 0.97 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| Water SCHEMBL9407657 | 0.97 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL27386931 | 0.97 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| Hydrochloric Acid SCHEMBL28211778 | 0.97 | ALDH1A1 (0.55) | ALDH1A1HPGDMMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| US-20230046680-A1 | NOVEL HETEROARYL-SUBSTITUTED AMINOALKYL AZOLE COMPOUNDS AS PESTICIDES | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-02-16 | — | — | US | claimed |
| EP-3956325-A1 | NOVEL HETEROARYL-SUBSTITUTED AMINOALKYL AZOLE COMPOUNDS AS PESTICIDES | Bayer Animal Health GmbH (DE) | 2022-02-23 | — | — | EP | claimed |
| US-11208396-B2 | Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-12-28 | — | — | US | claimed |
| WO-2020212235-A1 | NOVEL HETEROARYL-SUBSTITUTED AMINOALKYL AZOLE COMPOUNDS AS PESTICIDES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-10-22 | — | — | WO | claimed |
| EP-3209296-B1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-07-10 | — | — | EP | claimed |
| US-10072025-B2 | Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-11 | — | — | US | claimed |
| EP-2953940-B1 | PIPERIDIN-1-YL AND AZEPIN-1-YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2018-08-22 | — | — | EP | claimed |
| CN-108290055-A | The oxime compound of agonist as muscle M1 and/or M4 receptor | 赫普泰雅治疗有限公司 | 2018-07-17 | — | — | CN | claimed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | claimed |
| US-6423689-B1 | Peptidyl calcium channel blockers | WARNER-LAMBERT COMPANY | 2002-07-23 | — | — | US | claimed |
| US-6362174-B1 | ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | claimed |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | RAFFERTY MICHAEL FRANCIS (US) | 2002-03-07 | — | — | US | claimed |
| US-6316440-B1 | TREATMENT OF STROKE, HEAD TRAUMA, CEREBRAL ISCHEMIA, PAIN AND EPILEPSY | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | claimed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | claimed |
| WO-2000006559-A1 | REDUCED DIPEPTIDE ANALOGUES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | claimed |
| WO-1999055688-A1 | SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | claimed |
| WO-1999007689-A1 | ANILINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1999-02-18 | — | — | WO | claimed |
| WO-1993011669-A1 | USE OF 3-PHENYLURACIL DERIVATIVES FOR THE DESICCATION AND ABSCISSION OF PLANT PARTS | BASF AKTIENGESELLSCHAFT (DE) | 1993-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | ALDH1A1 1243/4885HPGD 1030/4885MMP1 4620/4885 |
| US-20230046680-A1 | NOVEL HETEROARYL-SUBSTITUTED AMINOALKYL AZOLE COMPOUNDS AS PESTICIDES | DDT, CRY1, CYP4F3 | ALDH1A1 3433/4885HPGD 4628/4885MMP1 3890/4885 |
| US-20010023249-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | ALDH1A1 943/4885HPGD 1583/4885MMP1 1781/4885 |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | CACNA1E, RYR1, CACNA1B | ALDH1A1 3308/4885HPGD 3640/4885MMP1 1742/4885 |
| US-10072025-B2 | Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors | JAK1, JAK2, JAK3 | ALDH1A1 2779/4885HPGD 853/4885MMP1 1899/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | ALDH1A1 1243/4885HPGD 1030/4885MMP1 4620/4885 |
| US-11208396-B2 | Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor | CHRM1, CHRM2, CHRM4 | ALDH1A1 1895/4885HPGD 1619/4885MMP1 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.